Risk factors for venous thromboembolic events in cancer patients

被引:169
作者
Kröger, K
Weiland, D
Ose, C
Neumann, N
Weiss, S
Hirsch, C
Urbanski, K
Seeber, S
Scheulen, ME
机构
[1] Univ Essen Med Sch, Dept Angiol, D-45122 Essen, Germany
[2] Univ Essen Med Sch, Inst Med Informat Biometry & Epidemiol, D-45122 Essen, Germany
[3] Univ Essen Med Sch, Dept Internal Med Canc Res, D-45122 Essen, Germany
关键词
deep vein thrombosis; risk assessment; cancer; chemotherapy;
D O I
10.1093/annonc/mdj068
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer patients of the Department of Internal Medicine (Cancer Research) of the Essen University Medical School (Tumor Clinics), Germany, were examined and questioned with the aim of identifying those who run a high risk of deep vein thrombosis (DVT). Patients and methods: Between September 2002 and April 2003, cancer therapy and DVT risk factors of 507 cancer patients (53% males, 47% females, mean age 56 +/- 12 years) were documented. During a mean follow-up of 8 +/- 5 months, 60 patients (12%) suffered from new venous thromboembolic events (VTE): 28 at the lower limb, 25 at the upper limb and 13 pulmonary embolisms. Results: The following factors were considered as predictive for an increased VTE risk: inpatient treatment (P < 0.0001), prior DVT in medical history (P = 0.0275), DVT in family (P = 0.0598), chemotherapy (P = 0.0080), fever (P = 0.0093) and CRP (P < 0.001). After combining factors in one variable (number of factors) the predicted VTE risk increased with the number of factors in both outpatients (OR 1.85, 95% CI 1.18-2.88, P = 0.0071) and inpatients (OR 2.34, 95% CI 1.63-3.36, P <= 0.0001). In the absence of all these factors the predicted VTE risk was 2.3%, increasing to 72% if all were present. Conclusions: In cancer patients the risk of VTE steadily increases with the number of risk factors, and identification of patients at high risk is possible.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 26 条
[21]   The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer [J].
Mills, PJ ;
Parker, B ;
Jones, V ;
Adler, KA ;
Perez, CJ ;
Johnson, S ;
Cohen-Zion, M ;
Marler, M ;
Sadler, GR ;
Dimsdale, JE ;
Ancoli-Israel, S .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :4998-5003
[22]   Cancer and thromboembolic disease: how important is the risk of thrombosis? [J].
Prandoni, P .
CANCER TREATMENT REVIEWS, 2002, 28 (03) :133-136
[23]  
RONNING M, 2002, EUR J CLIN PHARMACOL, V56, P723
[24]  
Sallah S, 2002, THROMB HAEMOSTASIS, V87, P575
[25]   A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients [J].
Samama, MM ;
Cohen, AT ;
Darmon, JY ;
Desjardins, L ;
Eldor, A ;
Janbon, C ;
Leizorovicz, A ;
Nguyen, H ;
Olsson, CG ;
Turpie, AG ;
Weisslinger, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :793-800
[26]   Risk factors for deep vein thrombosis in inpatients aged 65 and older: A case-control multicenter study [J].
Weill-Engerer, S ;
Meaume, S ;
Lablou, A ;
Piette, F ;
Saint-Jean, O ;
Sachet, A ;
Beinis, JY ;
Gallinari, C ;
Grancher, AS ;
Vincent, JP ;
Naga, H ;
Belmin, J ;
Salvatore, R ;
Kazes, M ;
Pautas, E ;
Boiffin, A ;
Piera, JB ;
Duviquet, M ;
Knafo, D ;
Piau, A ;
Miric, D ;
Jean, A ;
Bellamy, V ;
Tissandier, O ;
Le Blanche, AF .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (08) :1299-1304